论文部分内容阅读
目的:探讨早发型子痫前期抗凝治疗的临床效果及安全性。方法:将早发型子痫前期患者29例随机分为3组:A组10例,给予常规治疗;B组10例,在常规治疗的基础上加用低分子肝素治疗;C组9例,加用丹参治疗。观察3组患者临床指标的变化。结果:3组患者纳入研究时,临床指标无差异(P>0.05)。经治疗,B、C两组的临床疗效评分显著高于A组(14.2±2.1、12.9±2.8、9.5±3.9),P<0.05,期待治疗时间显著延长〔(18.2±7.2)天,(14.0±4.6)天、(10.1±3.4)天〕,P<0.05,纤维蛋白原(Fbg)及D-二聚体(D-D)显著降低。B组的新生儿体重及Apgar评分显著高于A组,而C组与A组相比差异无统计学意义。3组产后出血量无明显差异。结论:抗凝治疗有助于提高早发型子痫前期孕妇的治疗效果,对母儿安全。
Objective: To investigate the clinical effect and safety of anticoagulant therapy for preeclampsia. Methods: 29 cases of early-onset preeclampsia were randomly divided into 3 groups: group A, 10 cases, given conventional treatment; group B, 10 cases, based on routine treatment plus low molecular weight heparin; group C, 9 cases, plus Salvia treatment. The changes of clinical indexes in 3 groups were observed. Results: The three groups of patients included in the study, no difference in clinical indicators (P> 0.05). After treatment, the clinical efficacy scores in group B and C were significantly higher than those in group A (14.2 ± 2.1, 12.9 ± 2.8, 9.5 ± 3.9, P <0.05), and the expected treatment time was significantly longer (18.2 ± 7.2 days, ± 4.6 days, 10.1 ± 3.4 days], P <0.05, and fibrinogen (Fbg) and D-dimer (DD) decreased significantly. Neonatal weight and Apgar score in group B were significantly higher than those in group A, but there was no significant difference between group C and group A. 3 postpartum hemorrhage no significant difference. Conclusion: Anticoagulant therapy can improve the therapeutic effect of pregnant women with early-onset preeclampsia and have safety for both mother and child.